So I think I said in my remarks, Tayo, that the suburban Waltham market is very strong right now. It's probably as close to where it was in sort of the early -- late 2000, 2001 time frame, than it's ever -- than it's been since then. I mean it's -- there is literally not a block of 150,000 square feet of quality space between -- in Lexington or Waltham right now, which means that build to suits are sort of part of the dialogue. And we've seen rents go, in the last 1.5 years, from mid 20s to the low 40s for the best space in the marketplace in those buildings like Bay Colony and Waltham Woods and CityPoint and Wellesley Office Park and Riverside, which are sort of the -- those are the higher quality buildings. And none of those buildings have a block of space that's in excess of probably 40,000 or 50,000 square feet. So that market has just been a consistent stronger market with better demand, and it's really been life sciences companies, some of them coming out of Cambridge and some of them being located in the Waltham-Lexington market and just expanding. Cubist Pharmaceuticals being the most significant of those. In Princeton, the -- I don't think Northern New Jersey, in total, has really had a strong recovery. But we have been the fortunate beneficiary, and we've worked hard at it, to attracting some pharmaceutical companies, particularly foreign pharmaceutical companies, that have gone through some explosive growth, and we did some things to entice them to come to Carnegie Center that have worked out. And so a company like Otsuka Pharmaceuticals, we started out and we gave them 23,000 square feet of, basically, free space for 6 months. And now, they've leased 140,000 square feet and they're talking about leasing another 80,000 square feet of space. So good things happen when you establish a relationship with a great customer and you treat them right. And so we have just been the beneficiary of some really strong organic growth within the Princeton portfolio. And as those companies do well, they become more attractive places for companies that are like them. And so we've seen a significant amount of other foreign pharmaceutical interest in the Princeton, and particularly in the Carnegie Center portfolio, and we don't think that, that is a sort of a quarterly phenomena. We think it's a consistent trend.